May/June

As we debate who should pay for health care and how, it is critical to make clear what we expect to get for those payments: high-quality, cost-effective care that improves patient outcomes—in other words, value.

The oncology pharmaceutical market is rapidly growing and changing.

Ovarian cancer has been dubbed "the silent killer" because of its overall 5-year survival rate of 47%: By the time a woman receives the diagnosis, the prognosis is unfavorable.

What can health systems do to provide a seamless journey during a time of uncertainty?

Technological advancements empower patients to manage their own health.

All stakeholders in the health care continuum should always remember that there is a person at the end of their businesses who depends on them to survive and have a high quality of life.

On July 20, 2018, Pfizer Inc announced the FDA approval of filgrastim-aafi (Nivestym), a biosimilar to Amgen’s biologic Neupogen (filgrastim).

On February 6, 2019, the Department of Health and Human Services (HHS) proposed a rebate rule, Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees.

Although free drug starter programs are commonplace in the specialty pharmacy space, they vary widely in the marketplace.

USP encompasses training, assessment, and standard operating procedures to ensure personnel are properly prepared.

In a Specialty Pharmacy Times® Practice Pearls video series, expert panelists convened to discuss the challenges and best practices for dispensing multiple myeloma medications.

If you want to be a player in specialty pharmacy, oncology is the place to be.

Welcome to the ninth annual Specialty Pharmacy Times oncology issue, in which we focus on the challenges and progress associated with treating cancer in the specialty space.